Stemsynergy Therapeutics, Inc.

Miami, FL 33136

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $5.53MM
First Award Date 09/17/10
Most Recent Award Date 09/01/17

Key Personnel

Last Name Name Awards Contact
Orton Darren Orton 10
GUERRA MARCY LYNN GUERRA 1

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-16-008
Budget: 09/01/17 - 08/31/18

ABSTRACT Colorectal cancer (CRC) represents the fourth most commonly diagnosed cancer with 134,490 new cases each year. Unfortunately, CRC results in a disproportionate number of deaths (49,190 projected in 2016) due to advanced stage at diagnosis, the aggressive phenotype of the disease and lack of effective therapeutics. Greater than 90% of CR...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/16/16 - 08/31/17

ABSTRACT Burns represent one of the most traumatic and debilitating injuries affecting over 2 million people in the United States. Reparative processes occurring after acute burn injury ultimately result in fibrosis (scarring). In experimental systems, WNT pathway activation promotes scarring, while inhibition leads to regeneration. We have iden...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/05/16 - 08/31/17

? DESCRIPTION (provided by applicant): Triple negative breast cancer (TNBC) represents an aggressive tumor type with a distinct lack of effective treatment options. Standard-of-care chemotherapy regimens typically produce a partial response followed by regression months to years later. This Phase I application tests the hypothesis that, in s...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is the most common lung cancer. Half of NSCLC shows WNT activation, marking poor survival. StemSynergy Therapeutics Inc (SSTI) has identified a family of WNT inhibitors based on a novel chemical scaffold, with our lead molecule (SST-215) demonstrating efficacy against WNT-dr...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 03/01/15 - 02/28/17

? DESCRIPTION (provided by applicant): The tumor suppressor Adenomatous Polyposis Coli (APC) directs degradation of ?-catenin, a central signaling protein in the WNT pathway. Germline loss-of-function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis (FA...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/16/14 - 08/31/15

DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is the most common lung cancer. Half of NSCLC shows WNT activation, marking poor survival. StemSynergy Therapeutics Inc (SSTI) has identified a family of WNT inhibitors based on a novel chemical scaffold, with our lead molecule (SST-215) demonstrating efficacy against WNT-dr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fundamental to stem cells and cancer stem cells. The World Health Organization estimates that over 12 million cases of cancer were diagnosed in 2007 a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/21/12 - 08/31/13

DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fundamental to stem cells and cancer stem cells. The World Health Organization estimates that over 12 million cases of cancer were diagnosed in 2007 a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/20/12 - 08/31/13

DESCRIPTION (provided by applicant): Despite significant advancements in modern medicine with regards to surgery, radiation therapy and imaging of tumors, the survival rate for patients with non-small-cell lung carcinoma (NSCLC) remain almost identical to 20 years ago. Current therapies targeting the proliferative mechanisms of NSCLC cancers suc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/17/10 - 03/31/12

DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fundamental to stem cells and cancer stem cells. The World Health Organization estimates that over 12 million cases of cancer were diagnosed in 2007 an...

Load More